These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9558383)

  • 1. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
    Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
    Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
    Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
    Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q; Schroeder JA; Kuether EL; Montgomery RR
    J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
    Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
    Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.
    Connelly S; Andrews JL; Gallo-Penn AM; Tagliavacca L; Kaufman RJ; Kaleko M
    Thromb Haemost; 1999 Feb; 81(2):234-9. PubMed ID: 10063998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
    Scallan CD; Lillicrap D; Jiang H; Qian X; Patarroyo-White SL; Parker AE; Liu T; Vargas J; Nagy D; Powell SK; Wright JF; Turner PV; Tinlin SJ; Webster SE; McClelland A; Couto LB
    Blood; 2003 Sep; 102(6):2031-7. PubMed ID: 12738670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
    Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
    Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete short-term correction of canine hemophilia A by in vivo gene therapy.
    Connelly S; Mount J; Mauser A; Gardner JM; Kaleko M; McClelland A; Lothrop CD
    Blood; 1996 Nov; 88(10):3846-53. PubMed ID: 8916949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
    McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
    J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
    Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
    Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
    J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
    Andrews JL; Weaver L; Kaleko M; Connelly S
    Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
    VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.